BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Commission (EC) has granted a marketing authorisation for Roclanda®

AIM ImmunoTech Inc. and its CEO Thomas K. Equels announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’ mother over this past weekend.

Infrastructure Projects Completed Have Almost Tripled Treatment Capacity and Company is Well-Positioned with Strong Mailback Inventory Levels and Production Schedule

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, provided a corporate update and highlighted key milestones anticipated in 2021.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that it has been awarded a research grant of $995,862.51 from The Michael J. Fox Foundation for Parkinson’s Research

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2020 revenue.

RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, reported preliminary financial results for the fourth quarter and full year ended December 31, 2020.

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year - - Total Epidiolex ® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year – - Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 - LONDON and CARLSBAD, Calif., Jan. 11, 2021

Eligo Bioscience SA announced that it has entered into a research and option agreement with GlaxoSmithKline aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation.